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Polycomb group (PcG) protein BMI1 is an important regulator of oncogenic phenotype and is often overexpressed in several human malignancies including breast cancer. prostate. and lung cancers. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] As a result of this overexpression, cellular senescence is bypassed in malignant cells, and their replicative lifespan is extended. [15] [16] [17] [18] PcG proteins form multi-subunit complexes called polycomb repressive complexes (PRCs), which maintain chromatin in a transcriptionally inactive state and repress expression of tumor suppressors. 1, 2 BMI1 is main constituent of PRC1, which catalyzes the mono-ubiquitination of histone H2A at lysine 119 (H2AUb), while PRC2
catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3). Recently, there has been increasing evidence that saponins are able to inhibit tumor cell proliferation and act as chemotherapeutic agents. 20, 21 Timosaponin A-III is thought to induce autophagy and subsequent mitochondrial-dependent apoptotic cell death, mediated by increased production of reactive oxygen species (ROS), and related mitochondrial dysfunction. 21, 22 Timosaponin A-III mediated cell death may also involve the disruption of the mTOR pathway. 23 The detailed mechanism of TA-III induced inhibition of cell proliferation and oncogenic phenotypes is poorly understood. It is also not clear whether TA-III may induce other notable tumor suppressive phenotypes such as cellular senescence.
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BMI1 is overexpressed in many cancers and known to upregulate oncogenic phenotypes including cancer stem cell (CSC) phenotype. [25] [26] [27] BMI1 is also known to regulate cellular senescence via regulation of p16INK4a, 16 and p16INK4a-independent targets including WNT inhibitors and certain tumor suppressive miRNAs. [28] [29] [30] We hypothesized that TA-III may inhibit BMI1 expression and/or PRC1 activity, which may result in inhibition of cancer growth by TA-III. Here we studied the regulation of BMI1 expression and modulation of BMI1 induced oncogenic phenotypes by TA-III in breast cancer cells. Breast cancer is a heterogenous disease that consists of distinct subtypes based on the molecular profiles. 31 The most aggressive subtype known as triple negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and Her2/neu receptors, and is refractory to the receptor blocking therapies. 32 At present, very little is known about the TNBC targeting therapeutics. 32 Hence, we studied the growth inhibitory effect of TA-III in both non-TNBC and TNBC cell lines. We report that TA-III strongly inhibits BMI1 expression, and that inhibition of BMI1 by TA-III mediates its tumor suppressive activities in both TNBC and non-TNBC cells. BMI1 is transcriptionally regulated by wellknown oncogenic factor c-Myc. 33 Our studies further suggest that TA-III Stable MDA-MB-231 cell line expressing BMI1 was generated by expressing BMI1 using pBabe-puro retroviral vector overexpressing wildtype BMI1 as described previously. 28, 29 Wild-type and E-box mutant version of BMI1 promoter-reporter has been described previously. 33 The promoter-reporter constructs were transiently transfected into 293T cells using calcium phosphate method, cells were then treated with TA-III, and promoter-reporter assays were performed using Dual-Luciferase®
Reporter Assay System (Promega, Madison, WI) as described. GAPDH was used as a control. For miRNA analysis, total small non-coding RNA was extracted using a Qiagen kit, and used to prepare cDNA with a miRNA cDNA synthesis kit. The miRNA cDNA synthesis kit as well as miR-141, miR-200c, and RNU6B specific primers were obtained from Quanta Biosciences (Gaithersburg, MD). The PCR amplification was carried out as described previously.
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2.5 | Proliferation, migration invasion, and wound healing assays
The effect of Timosaponin A-III on proliferation was determined by an MTT assay. Migration and Invasion assays were carried out as described. 29, 30 Briefly, MDA-MB-231 and MCF7 cells were plated in TA-III in both of these cell lines. Using a dose-response experiment, the IC50 of TA-III in these cell lines was determined to be 2 μM (Suppl. Figure S1 ). Next, cells were treated with 2 and 4 μm TA-III for 48 h, and cell proliferation was measured using MTT assay ( Figure 1A) . The results showed that TA-III strongly decreased cell proliferation of both cell lines in a dose-dependent manner ( Figure 1A ). Next, we examined whether TA-III inhibits oncogenic/transformed phenotypes such as growth in soft-agar, migration, and invasion of breast cancer cells. soft-agar and were either mock-treated or treated with TA-III as described in the legend of Figure 1 . The results showed that TA-III strongly inhibits ability of breast cancer cells to form colonies in soft-agar ( Figure 1B) . Next, we determined the effects of TA-III-treatment on migration and invasion of MDA-MB-231 cells, which are known to be highly invasive and migratory.
The assays were performed as described. 30 The number of migrated and invaded cells were counted per high power field (HPF), and images were captured ( Figure 1C, 1D) . The results show that TA-III strongly inhibits both migration and invasion of MDA-MB-231 cells in a dose-dependent manner.
The inhibitory effect of TA-III on migration was further confirmed by wound healing assay (Suppl. Figure S2 ). The assay further showed that TA-III effect on migration is noticeable even at 12 h of treatment. Thus, TA-III is able to inhibit multiple oncogenic phenotypes of breast cancer cells.
Induction of replicative or premature cellular senescence is considered a strong tumor-suppressive growth response. 24 To determine whether TA-III can induce premature senescence, we treated MDA-MB-231 and MCF7 cells with TA-III and performed senescence-associated-beta galactosidase (SA-β-gal) assay together with EdU (5′ ethynyl −2′-deoxyuridine, a thymidine analog) co-staining as described. 34 assays. We have previously shown that c-Myc regulates transcription of BMI1 gene via an E-box (c-Myc binding site) in its promoter. 33 We analyzed luciferase activity of a wild-type BMI1 promoter-reporter in TA-III-and mock-treated breast cancer cells. We also analyzed luciferase activity of BMI1 mutant promoter-driven reporter, in which c-Myc binding site (E-box) has been mutated. 33 The results indicated that while wild-type BMI1 promoter activity is decreased by TA-III treatment in a dose-dependent manner, the activity of the mutant promoter is not altered by TA-III treatment ( Figure 3D ). The ChIP assay was performed as described in section 2. The cross-linked chromatin from control and TA-III-treated cells was prepared and imumunoprecipitated using c-Myc mAb or IgG control as described in section 2. FIGURE 4 Exogenous BMI1 overcome Timosaponin A-III effects on cell proliferation. A, The control (B0) and exogenous BMI1 overexpressing (BMI1) MDA-MB-231 cells were generated using infection of pBabe-puro vector and pBabe-BMI1 retroviruses followed by selection of cells in puromycin as described in section 2. The cells were treated with TA-III, and cell proliferation was determined by the MTT assay as described in Figure 1A . B, Expression of BMI1, c-Myc, H2AK119Ub, total H2A, and β-actin was determined in MDA-MB-231 -B0 (control) and MDA-MB-231-BMI1 cells by Western blot analysis after the treatment with TA-III as described in Figure 3A . C, Expression of BMI1 in MDA-MB-231 -B0 (control) and MDA-MB-231-BMI1 cells was determined by qRT-PCR analysis using specific primers for BMI1 as described in Figure 3B overexpressing MDA-MB-231 cells, while proliferation of control B0 cells Although TA-III is known to induce autophagy and cell death, 20, 21 and these properties of the TA-III may account for some of the antioncogenic or tumor suppressor activity of the TA-III, we reasoned that it may also induce premature cell senescence, which is a well-known tumor suppressor phenotype. 24 Furthermore, it has been shown that TA-III induces mitochondrial reactive oxygen species (mtROS), 20, 21 which can also result in cell senescence . Hence, we reasoned that TA- 
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